<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123053</url>
  </required_header>
  <id_info>
    <org_study_id>SD-DAP-01</org_study_id>
    <nct_id>NCT05123053</nct_id>
  </id_info>
  <brief_title>Firdapse for Post-BOTOX Vocal Weakness</brief_title>
  <official_title>Amifampridine for the Treatment of Transient Vocal Weakness After OnabotulinumtoxinA Injection for Spasmodic Dysphonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botox injections into the thyroarytenoid muscle are a predictable and effective treatment for&#xD;
      SD, but typically result in transient symptoms of voice weakness and breathiness during the&#xD;
      first 2-3 weeks after injection. We hypothesize that voice weakness and breathiness after&#xD;
      Botox treatment can be alleviated using amifampridine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spasmodic dysphonia (SD) is a dystonia which results in vocal breaks. The mainstay of&#xD;
      treatment involves injections using Botox (onabotulinumtoxinA), a neuromuscular blocker which&#xD;
      inhibits pre-synaptic release of acetylcholine into the neuromuscular junction. Botox&#xD;
      injections into the thyroarytenoid muscle are a predictable and effective treatment for SD,&#xD;
      but typically result in transient symptoms of voice weakness and breathiness during the first&#xD;
      2-3 weeks after injection. These symptoms can be present for even longer if Botox is over-&#xD;
      dosed.&#xD;
&#xD;
      We hypothesize that these initial, transient symptoms of voice weakness and breathiness after&#xD;
      Botox treatment can be alleviated using amifampridine which acts at the neuromuscular&#xD;
      junction to increase synaptic presence of the neurotransmitter acetylcholine. In these&#xD;
      initial studies we will look at patients who have significant breathiness following an&#xD;
      injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Voice Handicap Index-10</measure>
    <time_frame>over 2 months</time_frame>
    <description>scale to assess the severity of problematic symptoms associated with the voice</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Post-BOTOX Vocal Weakness</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be given active drug and titrated up in 10mg increments (with max single dose being 30mg) until a change or drug side effect is noticed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifampridine</intervention_name>
    <description>10mg tablet</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Firdapse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years of age.&#xD;
&#xD;
          2. Capable of providing informed consent.&#xD;
&#xD;
          3. Confirmed physician diagnosis of spasmodic dysphonia.&#xD;
&#xD;
          4. Receives onabotulinumtoxinA for treatment of their spasmodic dysphonia.&#xD;
&#xD;
          5. Experiences significant breathiness ± 5 days following their injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of epilepsy and on medication/treatment for the same.&#xD;
&#xD;
          2. Women who are pregnant, expecting to get pregnant, or breastfeeding.&#xD;
&#xD;
          3. Any condition that, in the view of the Principal Investigator, places the subject at&#xD;
             risk, or subjects with poor treatment compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Rivner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charbonnier Professor Emeritus of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandy Quarles, MPH</last_name>
    <phone>706-721-0390</phone>
    <email>bquarles@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Bouchard, BS</last_name>
    <phone>706-721-0390</phone>
    <email>kbouchard@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy M Quarles, MPH</last_name>
      <phone>706-721-0390</phone>
      <email>bquarles@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristy Bouchard, BS</last_name>
      <phone>706-721-0390</phone>
      <email>kbouchard@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael H Rivner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BOTOX</keyword>
  <keyword>Onabotulinumtoxin</keyword>
  <keyword>Spasmodic Dysphonia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifampridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

